506 related articles for article (PubMed ID: 12154100)
1. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
Lacourcière Y
Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
[TBL] [Abstract][Full Text] [Related]
3. Sustained antihypertensive activity of telmisartan compared with valsartan.
Lacourcière Y; Krzesinski JM; White WB; Davidai G; Schumacher H
Blood Press Monit; 2004 Aug; 9(4):203-10. PubMed ID: 15311147
[TBL] [Abstract][Full Text] [Related]
4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
5. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
White WB; Lacourciere Y; Davidai G
Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
[TBL] [Abstract][Full Text] [Related]
7. Discordant responses to two classes of drugs acting on the renin-angiotensin system.
Sever PS; Chang CL
J Renin Angiotensin Aldosterone Syst; 2001 Mar; 2(1):25-30. PubMed ID: 11881062
[TBL] [Abstract][Full Text] [Related]
8. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension.
White WB; Punzi HA; Murwin D; Koval SE; Davidai G; Neutel JM
J Clin Hypertens (Greenwich); 2006 Sep; 8(9):626-33. PubMed ID: 16957424
[TBL] [Abstract][Full Text] [Related]
9. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Stergiou GS; Skeva II; Baibas NM; Roussias LG; Kalkana CB; Achimastos AD; Mountokalakis TD
J Cardiovasc Pharmacol; 2000 Jun; 35(6):937-41. PubMed ID: 10836730
[TBL] [Abstract][Full Text] [Related]
10. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
11. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
Prisant LM; Krum H; Roniker B; Krause SL; Fakouhi K; He W
J Clin Pharmacol; 2003 Nov; 43(11):1203-10. PubMed ID: 14551174
[TBL] [Abstract][Full Text] [Related]
12. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.
Mallion J; Siche J; Lacourcière Y
J Hum Hypertens; 1999 Oct; 13(10):657-64. PubMed ID: 10516734
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
[TBL] [Abstract][Full Text] [Related]
17. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
18. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
19. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
[TBL] [Abstract][Full Text] [Related]
20. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]